Drug Trial News

RSS

Pfizer's axitinib Phase 3 trial in advanced renal cell carcinoma meets primary endpoints

Pfizer Inc. today announced data from the pivotal Phase 3 AXIS 1032 trial, showing that in patients with previously treated advanced renal cell carcinoma, axitinib significantly extended progression-free survival at the 47th Annual American Society of Clinical Oncology meeting in Chicago from June 3-7, 2011.

19 May 2011

Nektar to present new NKTR-102 Phase 2 clinical data in multiple cancers at ASCO annual meeting

Nektar Therapeutics today announced that new Phase 2 clinical data for NKTR-102, Nektar's lead oncology candidate being evaluated in multiple cancer indications, have been selected for presentation at the 47th Annual Meeting of the American Society of Clinical Oncology being held June 3-7, 2011 in Chicago, Illinois.

19 May 2011

Mpex, Synteract partner for cystic fibrosis fundraising event

Synteract, Inc., a full-service, global contract research organization, and Mpex Pharmaceuticals, a biopharmaceutical company developing new therapies to combat the growing issue of antibiotic resistance, have partnered for the second annual Great Strides fundraiser to benefit cystic fibrosis.

19 May 2011

Biothera begins dosing in Imprime PGG and cetuximab combination Phase III trial for colorectal cancer

Biothera began dosing patients today in a Phase III trial evaluating Imprime PGG in combination with cetuximab as a potential new treatment for recurrent or progressive KRAS wild-type colorectal cancer.

19 May 2011

Pharma Two B plans to initiate P2B001 Phase II study in Parkinson's disease

Pharma Two B announced today it is planning a Phase II study of its new combination therapy, P2B001, in development as a treatment for the early stages of Parkinson's disease. Assuming regulatory approval and the necessary financing, the company plans to commence the Phase II trial in Q4 2011.

18 May 2011

New data on personalized approaches for skin, ovarian and lung cancer to be presented at ASCO meeting

Genentech, a member of the Roche Group, today announced that data showing new personalized approaches for people with skin and lung cancer, plus new data with Avastin in ovarian cancer, will be presented at the 47th Annual Meeting of the American Society of Clinical Oncology.

18 May 2011

New denosumab Phase III trial data in high-risk prostate cancer presented at AUA conference

Data on the use of denosumab (Xgeva) to improve bone metastases-free survival in men with high-risk prostate cancer was presented at the American Urological Association conference today for the first time.

18 May 2011

JCO publishes Micromet's blinatumomab Phase 2 trial data in acute lymphoblastic leukemia

Micromet, Inc. today announced that data from a Phase 2 clinical trial of the Company's lead product candidate blinatumomab in patients with minimal residual disease positive acute lymphoblastic leukemia were published in the May 16th on-line edition of the Journal of Clinical Oncology.

18 May 2011

Bayer HealthCare to present results on investigational oncology compounds at ASCO annual meeting

Bayer HealthCare Pharmaceuticals, Inc. announced today that data evaluating several of its investigational oncology compounds will be presented in a scientific forum at the 2011 Annual Meeting of the American Society of Clinical Oncology, June 3-7, in Chicago, IL.

18 May 2011

CITN selects Cytheris' CYT107 for initial clinical trials at network institutions

Cytheris SA and the Cancer Immunotherapy Trials Network, a new initiative in immunotherapy funded by the National Cancer Institute with its Central Operations and Statistical Center headquartered at Fred Hutchinson Cancer Research Center, Seattle, Washington, today announced the selection of recombinant human interleukin-7, the investigational multifunctional cytokine under development by Cytheris, as one of the first immunotherapeutic agents proposed for initial clinical trials at network institutions.

18 May 2011

Amgen announces primary results from XGEVA Phase 3 trial in castrate-resistant prostate cancer

Amgen today announced primary results of a pivotal Phase 3 trial demonstrating that XGEVA significantly increased bone metastasis-free survival for more than four months in men with castrate-resistant metastatic prostate cancer that has not yet spread to bone.

18 May 2011

Avanafil long-term phase 3 trial in erectile dysfunction meets primary endpoints

VIVUS, Inc. today announced that positive results from a pivotal phase 3 open-label clinical trial evaluating long-term safety and efficacy of the investigational drug avanafil for the treatment of erectile dysfunction were presented at the 2011 Annual Meeting of the American Urological Association in Washington, D.C.

18 May 2011

Endo and Bioniche present Urocidin Phase III trial preliminary results at 2011 AUA annual meeting

Endo Pharmaceuticals and Bioniche Life Sciences today presented Phase III trial results for the intravesical formulation of Mycobacterial cell wall-DNA complex (MCC), known as Urocidin, during a podium presentation at the 2011 American Urological Association annual meeting in Washington, D.C.

18 May 2011

Positive results from Astellas Pharma's mirabegron phase III trial in overactive bladder

Astellas Pharma US, Inc., U.S. subsidiary of Astellas Pharma Inc., today announced the results of a pivotal phase III clinical trial for mirabegron, the first of a new class of compounds under development for the treatment of overactive bladder (OAB), which show mirabegron significantly improves key OAB symptoms – urinary incontinence and frequency of micturition compared with placebo.

18 May 2011

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Canada

CEL-SCI Corporation announced today that it has commenced its global Phase III clinical trial for Multikine, the Company's flagship immunotherapy, in Canada at St. Joseph's Healthcare - Hamilton, Ontario.

18 May 2011

Anacor Pharmaceuticals initiates AN2728, AN2898 Phase 2 trial in mild-to-moderate atopic dermatitis

Anacor Pharmaceuticals announced today that the first patient has been dosed in a Phase 2 trial of AN2728 and AN2898 to determine safety, tolerability and efficacy of the two compounds for the topical treatment of mild-to-moderate atopic dermatitis.

18 May 2011

Preliminary topline results from Teva, CureTech's CT-011 Phase II trial in Diffuse Large B Cell Lymphoma

Teva Pharmaceutical Industries Ltd. and CureTech, a portfolio company of Teva and Clal Biotechnology Industries announced today preliminary topline results for CT-011, an investigational anti-PD-1 monoclonal antibody.

17 May 2011

Thrombolytic therapy linked to poor survival in pulmonary embolism patients with normal blood pressure

Although so-called clot-busting drugs are commonly used in the treatment of some patients with blood clots in the lungs, a new study conducted by researchers in Spain and the U.S. indicates the agents do not appear to be any more effective than traditional blood thinners for the majority of these patients.

17 May 2011

Sanofi hopes to launch dengue vaccine in 2014

France's Sanofi-Pasteur, the world's largest vaccine maker, said Friday it hopes to introduce a dengue vaccine in 2014 to some high-risk nations, AlertNet reports. The vaccine is in the last stage of clinical testing in Australia, and the company said it hopes to produce 100 million doses of the vaccine annually, according to the news agency.

17 May 2011

SYMBICORT long-term comparative study data in African American asthma patients presented at ATS 2011

AstraZeneca today announced results from a long-term study comparing SYMBICORT Inhalation Aerosol 160/4.5 mcg with budesonide pressurized metered-dose inhaler 160 mcg in self-reported African American patients with moderate to severe persistent asthma.

17 May 2011

Drug Trial News

Pfizer's axitinib Phase 3 trial in advanced renal cell carcinoma meets primary endpoints

Nektar to present new NKTR-102 Phase 2 clinical data in multiple cancers at ASCO annual meeting

Mpex, Synteract partner for cystic fibrosis fundraising event

Biothera begins dosing in Imprime PGG and cetuximab combination Phase III trial for colorectal cancer

Pharma Two B plans to initiate P2B001 Phase II study in Parkinson's disease

New data on personalized approaches for skin, ovarian and lung cancer to be presented at ASCO meeting

New denosumab Phase III trial data in high-risk prostate cancer presented at AUA conference

JCO publishes Micromet's blinatumomab Phase 2 trial data in acute lymphoblastic leukemia

Bayer HealthCare to present results on investigational oncology compounds at ASCO annual meeting

CITN selects Cytheris' CYT107 for initial clinical trials at network institutions

Amgen announces primary results from XGEVA Phase 3 trial in castrate-resistant prostate cancer

Avanafil long-term phase 3 trial in erectile dysfunction meets primary endpoints

Endo and Bioniche present Urocidin Phase III trial preliminary results at 2011 AUA annual meeting

Positive results from Astellas Pharma's mirabegron phase III trial in overactive bladder

CEL-SCI initiates Multikine Phase III trial for head and neck cancer in Canada

Anacor Pharmaceuticals initiates AN2728, AN2898 Phase 2 trial in mild-to-moderate atopic dermatitis

Preliminary topline results from Teva, CureTech's CT-011 Phase II trial in Diffuse Large B Cell Lymphoma

Thrombolytic therapy linked to poor survival in pulmonary embolism patients with normal blood pressure

Sanofi hopes to launch dengue vaccine in 2014

SYMBICORT long-term comparative study data in African American asthma patients presented at ATS 2011

How agentic AI is reshaping laboratory workflows

Fourier 80: bringing benchtop NMR systems to the laboratory

How industrial hygiene flow calibration supports defensible exposure data

Latest News